deltatrials
Active Not Recruiting PHASE2 NCT03879577

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)

Sponsor: University of Chicago

Conditions Breast Cancer Breast Cancer Female Breast Cancer Stage II Breast Cancer Stage III HER2-positive Breast Cancer
Interventions Docetaxel FEC Herceptin LHRH agonist Letrozole Tamoxifen
Updated 9 times since 2019 Last updated: Jan 2, 2026 Started: Nov 25, 2019 Primary completion: Mar 30, 2023 Completion: Sep 30, 2026

A PHASE2 clinical study on Breast Cancer and Breast Cancer Female, this trial is ongoing. The trial is conducted by University of Chicago and has accumulated 9 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

9 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. May 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

▶ Show 4 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  2. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Not Yet Recruiting → Active Not Recruiting

  3. Nov 2019 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

  4. Apr 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ibadan, Nigeria